NOTE: The content below contains the first few paragraphs of the printed article and the titles of the sidebars and boxes, if applicable.
Dr. Annalisa Jenkins
Dimension Therapeutics Names CEO
Dimension Therapeutics, a gene therapy company focused on developing novel treatments for rare diseases, has apppointed Annalisa Jenkins, MBBS, MRCP, CEO. Dr. Jenkins succeeds interim CEO Thomas Beck.
Dr. Jenkins brings to Dimension almost 20 years of experience in building and leading teams that advance programs from scientific research through clinical development, regulatory approval, and into healthcare systems globally. Before joining Dimension, Dr. Jenkins served as executive VP, head of global research and development, for Merck Serono, where she also led global medical affairs and quality.
Nora Therapeutics Names VP,
Strategic Marketing &
Nora Therapeutics, a biotechnology company focused on developing therapeutics to address unmet needs in reproductive medicine, has named Sandra Shpilberg VP, strategic marketing and commercial planning. Ms. Shpilberg is responsible for the development and implementation of marketing and commercial strategies for Nora’s lead compound, NT100.
Worldwide Clinical Trials appoints
New President and Chief
Peter Benton has joined Worldwide Clinical Trials, a CRO driven by global operational excellence integrated with acknowledged medical and scientific expertise.
As president and chief operating officer, Mr. Benton is responsible for leading WCT on its mission to facilitate the development of life-changing medicines by integrating clinical trials methodology, operational acumen and efficient technology.
Mr. Benton has a diverse background with significant senior executive level experience. He joins WCT from BioClinica, having served as executive VP and president for its e-clinical Solutions business, where he led overall strategy, sales, and operations.
INC Research Promotes VP of
Oncology and Hematology
INC Research has promoted Patrick Melvin to VP of oncology and hematology. Since joining INC Research in 2011, Mr. Melvin has successfully leveraged his experience in the clinical development process involving both non-malignant and malignant hematology. This activity has included the execution of multiple programs under FDA’s new breakthrough therapy designation, and has resulted in marketing approvals for new leukemia/lymphoma therapies in both the United States and Europe.
Medidata Appoints Chief
Medidata, a global provider of cloud-based solutions for clinical research in life sciences, has named Michael Capone as chief operating officer.
In the newly created COO role, he reports directly to Medidata’s CEO Tarek Sherif and President Glen de Vries. Mr. Capone joins Medidata from ADP, one of the world’s largest business-to-business software providers, where he served as corporate VP of product development and chief information officer.
ERT Appoints New President and CEO
ERT, a global solution provider for high-quality patient safety and efficacy endpoint data collection, has appointed Jim Corrigan as president and CEO. Mr. Corrigan previously served as executive VP and chief operating officer since August 2013.
STATEMENT OF OWNERSHIP,
1. Publication title: PharmaVOICE
2. Publication no.: #23626
3. Filing date: September 30, 2014
4. Issue frequency: published monthly except combined issues in July/August and Nov./Dec.
5. No. of issues published annually: 10
6. Annual subscription price: US: $190.
7. Complete mailing address of known office of publication: PharmaLinx LLC, 244 Jacobs Creek Road, Titusville, NJ 08560, Titusville, NJ 08560
8. Complete mailing address of headquarters or general business office of publisher: PharmaLinx LLC, 244 Jacobs Creek Road, Titusville, NJ 08560, Titusville, NJ 08560
9. Full names and complete mailing addresses of publisher, editor, and managing editor:
Lisa Banket, P.O. Box 327, Titusville, NJ 08560, Taren Grom, P.O. Box 327, Titusville, NJ 08560, and Denise Myshko, P.O. Box 327, Titusville, NJ 08560
10. Owner: Lisa Banket, Taren Grom, and
11. Known bondholders, mortgagees, and other security holders owning or holding 1 percent or more of total amount of bonds, mortgages, or other securities: (none)
13. Publication title: PharmaVOICE
14. Issue date for circulation data below:
15. Extent and nature of circulation (avg. no. copies each issue during preceeding 12 months and actual no. copies of single issue published nearest to filing date, respectively). Total no. copies – 18,015 and 18,000. Individual paid/requested mail subscriptions stated on Form 3541: 17,599 and 17,576. Sales through dealers and carriers, street vendors, counter sales, and other paid or requested distribution outside USPS: 24 and 10. Total paid and/or requested circulation: 17,623 and 17,586. Nonrequested copies stated on Form 3541: 0 and 0.
Free or nominal rate distributed outside the mail: 48 and 37. Total free or nominal rate distributed: 168 and 315. Total distribution: 17,839 and 17,938. Copies not distributed: 176 and 62. Total: 18,015 and 18,000. Percent paid and/or requested circulation: 98.7 and 98.0.
16. This statement of ownership will be printed in the November/December 2014 issue of this publication.
17. I certify that all information furnished on this form is true and complete. I understand that anyone who furnishes false or misleading information on this form or who omits material or information on the form may be subject to criminal sanctions (including fines and imprisonment) and/or civil sanctions (including civil penalties). (Signed) Marah Walsh, Founding Partner
Ritter Pharmaceuticals Names CEO
Ritter Pharmaceuticals, a privately held pharmaceutical company focused on gastrointestinal disorders, has named Michael Step CEO. Mr. Step was appointed to the company’s board of directors in 2011 and will continue to serve as a director. Andrew Ritter, the company’s founder, who previously served as president and CEO, will now hold the title of president while continuing as a director.
For the past nine years, he was senior VP of corporate development and a member of the executive committee of Santarus, until its sale to Salix Pharmaceuticals in January 2014.
Dr. Olivier Danos
Biogen Idec Names Senior VP,
Biogen Idec has named Olivier Danos, Ph.D., senior VP, gene therapy. Dr. Danos reports directly to Douglas Williams, Ph.D., executive VP, research and development, and is a member of Biogen Idec’s senior research and development leadership team.
Dr. Danos joins Biogen Idec from Kadmon Pharmaceuticals, where he served as senior VP, molecular medicine, synthetic biology and gene regulation.
Dr. David Hagerty
Conatus Pharmaceuticals Appoints Executive VP, Clinical Development
Conatus Pharmaceuticals, a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, has appointed David Hagerty, M.D., as executive VP, clinical development, with oversight responsibility for the company’s medical activities including clinical development, clinical operations, regulatory affairs, biostatistics, quality assurance, and drug safety.
Dr. Hagerty has been an independent consultant in clinical development since April 2013. He served as senior VP and chief medical officer at Ardea Biosciences from 2011 to 2013.
Dr. Israel Charo
ChemoCentryx Appoints Senior VP of Research
ChemoCentryx, a clinical-stage biopharmaceutical company focused on autoimmune diseases, inflammatory disorders and cancer, has appointed Israel Charo, M.D., Ph.D., senior VP of research. Dr. Charo has been a member of the ChemoCentryx scientific advisory board.
Before joining ChemoCentryx, Dr. Charo was a scientist-in-residence at Bay City Capital, a life sciences investment firm, since 2009. Dr. Charo is a senior investigator at the Gladstone Institute of Cardiovascular Disease in San Francisco, and Professor of Medicine at UCSF, where he studies the role of chemokines in leukocyte trafficking and inflammation. His group at UCSF cloned the chemokine receptor known as CCR2, and showed that it is a major driver for the recruitment of monocyte/macrophages to developing atherosclerotic lesions. Previously, Dr. Charo was one of the founding scientists of COR Therapeutics, subsequently acquired by Millennium, where he was part of the team that developed the platelet inhibitor Integrilin.
Dr. Peter Ho
Epizyme Appoints Chief Development Officer and VP, Business Development
Epizyme, a clinical-stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, has appointed Peter Ho, M.D., Ph.D., as chief development officer, and Michael Shih, as VP, business development.
Dr. Ho leads Epizyme’s clinical development, regulatory, and translational medicine functions.
Mr. Shih leads Epizyme’s partnership strategy and execution. Most recently, he served as senior director of business development at Forest Laboratories, where he was responsible for screening, sourcing and negotiating strategic partnership opportunities across several therapeutic areas, including oncology and oncology supportive care.
Dr. Pierre Beaurang
Dr. Arthur Sands
Nurix Adds to Senior
Nurix has appointed Pierre Beaurang, Ph.D., VP, business and corporate development.
Dr. Beaurang brings to Nurix almost 15 years of business and operational experience in the biotechnology industry. Before joining Nurix, he was part of the founding team of Five Prime Therapeutics, contributing to the conceptualization, creation and implementation of the company plan and serving in multiple operational and business development roles of increasing responsibility through his appointment as executive director of business development.
In other company news, Arthur Sands, M.D., Ph.D., has been named CEO. Dr. Sands succeeds interim CEO Mark Goldsmith, M.D., Ph.D., a partner at Third Rock Ventures, who will continue service to the company as chairman of its board of directors.
Before Nurix, Dr. Sands co-founded Lexicon Pharmaceuticals and served as president, CEO, and a director since 1995. He also serves as adjunct professor in the Department of Human and Molecular Genetics at Baylor College of Medicine.
Dr. David Cox
Dr. Dennis Kim
Announces Key Medical and
Ipsen Biopharmaceuticals has announced key hires as the company continues to build its executive management capabilities. The company has identified bolstering its presence in North America as a key strategic priority, and these additions to the senior leadership team represent an integral move forward in executing Ipsen’s continued growth.
David Cox, Ph.D., has been named VP, medical affairs oncology and endocrinology. He is responsible for leading medical affairs planning and activities for Ipsen’s oncology and endocrinology portfolio in North America. He has spent the majority of his 14-year career in medical affairs and clinical development roles; most recently he was the Americas Medical Strategy Lead at Eisai, managing medical directors and MSL teams, supporting the medical affairs strategy for the company’s oncology portfolio in North America.
Dennis Kim, M.D., has been named senior VP, North American Medical and Regulatory Affairs. He provides strategic direction and leadership for North American medical affairs, drug safety, and regulatory affairs for the oncology, endocrinology, and neurology franchises. Before joining Ipsen, he was the VP and head, medical affairs for Spectrum Pharmaceuticals.
Lynda Parker has been appointed VP, oncology and endocrinology business unit. She is responsible for developing the strategy and leading commercial execution of plans for oncology and endocrinology products, including Ipsen Biopharmaceutical’s first oncology launch, expected in neuroendocrine cancer. She most recently worked at inVentiv Health where she was responsible for building and launching multiple sales teams and products.
Dr. Bimal Shah
Premier Research Services
Bimal Shah, M.D., has been named VP of Premier Research Services. Dr. Shah, a practicing non-invasive cardiologist with vast experience in clinical research and hospital operations, provides strategic, clinical, analytical and research support to Premier Research Services.
Premier Research Services combines deep data, analytical expertise and relationships with 60% of the hospitals in the U.S., as well as biopharmaceutical and medical device manufacturers, to identify innovative ways to improve patient care and safely reduce costs.
Intouch Solutions Promotes Multiple Employees
Intouch Solutions, a marketing agency serving the pharmaceutical industry, has promoted seven employees.
Mike Brachtenbach, project manager, joined Intouch in January 2012 as a creative project manager.
Justin Clark, team lead, has excelled in technical project management and client service since he joined Intouch in August 2011 as a senior project manager.
Andrew Grojean, senior social media analyst, joined Intouch in May 2011 as an intern and was quickly hired as a social media analyst where he worked on client accounts with a specific focus on leveraging technology to increase channel engagement.
John Izbrand, senior director of quality services, joined Intouch in 2010 as a quality manager.
Allie McDowell, social media analyst, began her career at Intouch as an associate social media analyst in October 2012.
Kristine Wuelzer, senior quality analyst, joined Intouch in August 2011 as a quality analyst and has been active in planning and instrumenting automated quality testing to improve both the effectiveness and efficiency of software testing.
Yusuf Yaman, senior director of application development, joined Intouch in 2005 as a technical architect director and has played a critical role within Intouch’s development services.